MANKIND PHARMA
Quarterly Results Analysis [Dec2024]
MANKIND PHARMA Quarterly Results
Consolidated | Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹3,230 Cr | ₹3,077 Cr | ₹2,893 Cr | ₹2,441 Cr | ₹2,607 Cr | ₹2,708 Cr | ₹2,579 Cr | ₹2,053 Cr |
Expenses | ₹2,400 Cr | ₹2,226 Cr | ₹2,212 Cr | ₹1,850 Cr | ₹2,000 Cr | ₹2,025 Cr | ₹1,924 Cr | ₹1,636 Cr |
Operating Income | ₹830 Cr | ₹850 Cr | ₹682 Cr | ₹591 Cr | ₹607 Cr | ₹683 Cr | ₹655 Cr | ₹417 Cr |
Other Income | ₹77 Cr | ₹109 Cr | ₹101 Cr | ₹92 Cr | ₹70 Cr | ₹60 Cr | ₹59 Cr | ₹48 Cr |
Interest | ₹221 Cr | ₹7 Cr | ₹11 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹6 Cr | ₹5 Cr |
Depreciation | ₹192 Cr | ₹106 Cr | ₹108 Cr | ₹105 Cr | ₹110 Cr | ₹96 Cr | ₹87 Cr | ₹85 Cr |
Profit Before Tax | ₹494 Cr | ₹847 Cr | ₹664 Cr | ₹569 Cr | ₹558 Cr | ₹638 Cr | ₹620 Cr | ₹375 Cr |
Profit After Tax | ₹381 Cr | ₹656 Cr | ₹539 Cr | ₹474 Cr | ₹455 Cr | ₹508 Cr | ₹489 Cr | ₹291 Cr |
EPS | ₹9.22 | ₹16.31 | ₹13.39 | ₹11.76 | ₹11.33 | ₹12.51 | ₹12.15 | ₹7.13 |
Industry Peers & Returns | 1W | 1M | 1Y |
MANKIND PHARMA | -0.7% | -13.8% | 18.2% |
SUN PHARMACEUTICAL INDUSTRIES | -4.2% | -7.7% | 24.1% |
CIPLA | 3.3% | -4.8% | 6.5% |
DR REDDYS LABORATORIES | -2.4% | -12.8% | 1.1% |
ZYDUS LIFESCIENCES | -0.3% | -2.1% | 24.5% |
DIVIS LABORATORIES | -0.6% | -5.6% | 57.5% |
TORRENT PHARMACEUTICALS | 3.4% | -1.7% | 37.7% |
LUPIN | -3.2% | -12.7% | 39.3% |
AUROBINDO PHARMA | -2.4% | -12.5% | -0.3% |
MANKIND PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 4.99 % |
Y-o-Y | 23.90 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2024 | ₹3,230 Cr | 4.99 | |
Sep2024 | ₹3,077 Cr | 6.33 | |
Jun2024 | ₹2,893 Cr | 18.53 | |
Mar2024 | ₹2,441 Cr | -6.36 | |
Dec2023 | ₹2,607 Cr | -3.74 | |
Sep2023 | ₹2,708 Cr | 5.02 | |
Jun2023 | ₹2,579 Cr | 25.62 | |
Mar2023 | ₹2,053 Cr | - |
MANKIND PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -2.38 % |
Y-o-Y | 36.82 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2024 | ₹830 Cr | -2.38 | |
Sep2024 | ₹850 Cr | 24.68 | |
Jun2024 | ₹682 Cr | 15.34 | |
Mar2024 | ₹591 Cr | -2.54 | |
Dec2023 | ₹607 Cr | -11.16 | |
Sep2023 | ₹683 Cr | 4.25 | |
Jun2023 | ₹655 Cr | 57.15 | |
Mar2023 | ₹417 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -7.02 % |
Y-o-Y | 10.45 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2024 | 25.69% | -7.02 | |
Sep2024 | 27.63% | 17.28 | |
Jun2024 | 23.56% | -2.68 | |
Mar2024 | 24.21% | 4.08 | |
Dec2023 | 23.26% | -7.74 | |
Sep2023 | 25.21% | -0.71 | |
Jun2023 | 25.39% | 25.07 | |
Mar2023 | 20.3% | - |
MANKIND PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -41.94 % |
Y-o-Y | -16.28 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2024 | ₹381 Cr | -41.94 | |
Sep2024 | ₹656 Cr | 21.73 | |
Jun2024 | ₹539 Cr | 13.70 | |
Mar2024 | ₹474 Cr | 4.17 | |
Dec2023 | ₹455 Cr | -10.34 | |
Sep2023 | ₹508 Cr | 3.73 | |
Jun2023 | ₹489 Cr | 68.24 | |
Mar2023 | ₹291 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -44.68 % |
Y-o-Y | -32.42 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2024 | 11.8 % | -44.68 | |
Sep2024 | 21.33 % | 14.49 | |
Jun2024 | 18.63 % | -4.07 | |
Mar2024 | 19.42 % | 11.23 | |
Dec2023 | 17.46 % | -6.88 | |
Sep2023 | 18.75 % | -1.21 | |
Jun2023 | 18.98 % | 33.94 | |
Mar2023 | 14.17 % | - |
MANKIND PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -43.47 % |
Y-o-Y | -18.62 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2024 | ₹9.22 | -43.47 | |
Sep2024 | ₹16.31 | 21.81 | |
Jun2024 | ₹13.39 | 13.86 | |
Mar2024 | ₹11.76 | 3.80 | |
Dec2023 | ₹11.33 | -9.43 | |
Sep2023 | ₹12.51 | 2.96 | |
Jun2023 | ₹12.15 | 70.41 | |
Mar2023 | ₹7.13 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD